Current Research Shows Proenzymes Decreases Cell Proliferation and Migration, Induces Cell Differentiation, Impairs Angiogenesis and Reduces the Metastatic Potential of Cancer Stem Cells
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company’s scientific researchers, together with its joint research partners, Universities of Jaén and Granada, published key data in a peer reviewed journal, Expert Opinion on Biological Therapy, confirming the anti-tumor potential of a mixture of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Treatment with proenzymes sensitizes cancer stem cells (CSCs) which may allow standard treatment approaches, like chemotherapy and radiotherapy to be more effective. Expert Opinion on Biological Therapy is a peer-reviewed medical journal covering research on all aspects of biological therapies. The article is entitled “Trypinsogen and chymotrypsinogen: potent anti-tumor agents,” and can be accessed via the link: https://www.tandfonline.com/eprint/MJ7Y7EWCJI9CHESREZUC/full?target=10.1080/14712598.2021.1922666
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005041/en/
Main anti-tumor effects of Proenzymes (Photo: Business Wire)
The article is the fifth scientific publication published on the effects of proenzymes in cancer and fourth published in a peer reviewed journal. The current research demonstrates that novel pancreatic proenzyme formulations exert the following effects on CSCs:
“We continue to publish compelling scientific data confirming the effects of proenzymes against CSCs and its potential as a targeted therapy,” said Dr Julian Kenyon, Propanc’s Chief Scientific Officer, “There is currently significant interest in therapies that are not only more effective and less toxic, but critically, also support the immune function of patients. Given the current global pandemic situation, the risk of secondary infection in people afflicted with cancer undergoing chemotherapy of radiation is life threatening. This is yet another significant potential clinical application of proenzymes as a cancer treatment regimen.”
“It has been accepted in the medical community that pancreatic proenzymes exert significant effects on tissue repair inflammation and the immune system, but less understood in its role as an anti-cancer therapy, despite both phenomena being closely linked,” said Professor Macarena Perán, Department of Health Sciences, University of Jaén and Propanc’s Scientific Advisor. “Our research concludes that proenzymes as an adjuvant therapy in cancer has proved to be a successful strategy for reducing tumor size and improving the survival rate. These observations have tremendous potential clinical applications for late-stage cancer patients suffering from solid tumors. My team and I remain determined to assist the Propanc Team introducing this new approach to the medical and scientific community.”
About the University of Jaén:
The University of Jaén is among the Top 50 of the best young universities in the world according to THE (Times Higher Education). Likewise, the University of Jaén received the EFQM 500+ European Seal of Excellence, the highest level of recognition awarded by the Excellence in Management Club, as the official representative of the European Foundation for Quality Management (EFQM) in Spain. It also stands out in the field of computing, since the University of Jaén is among the 75 best universities in the world, according to Academic Ranking of World Universities (ARWU) 2017. The University of Jaén is repeatedly in the top 4% of universities worldwide, according to the Ranking Center for World University Rankings (CWUR), which annually collects the thousand best and most valued among the more than 25,000 existing universities. In addition, it is the fourth Spanish university that has obtained the highest score in the ranking of international student satisfaction, published by the STEXX International Studyportals Organization, in its 2016 version.
About the University of Granada:
The University of Granada is widely recognized internationally for its quality in higher education, teaching, research and outreach. National and international rankings reflect the University Granada’s position among the top universities in Spain and among the best in the world. In 2018, the University of Granada has further consolidated this dominant position – taking 278th place in the world and 3rd in Spain in the recently published Shanghai Academic Ranking of World Universities (ARWU 2018). Viewed from the perspective of its performance in specific academic subjects, the UGR has also set a new record, with a further 34 subjects taught at the University featuring in the 2018 ARWU — 12 more than in 2017. Furthermore, 5 of the University Granada’s subjects feature among the world top 100, marking another significant milestone.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s Registration Statement on Form S-1, Amendment No. 5, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 3, 2020, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.
Investor Relations and Media Contacts:
Mr. James Nathanielsz
Propanc Biopharma, Inc.
Source: Propanc Biopharma, Inc.
Released May 17, 2021